Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Launched by BAYER · Oct 10, 2005
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed and dated statement of informed consent
- • Completion of Protocol 307000A
- • Negative serum pregnancy test results
- • Agreement to adequate contraception, for female patients
- Exclusion Criteria:
- • Pregnancy or lactation
- • History of alcohol or drug abuse
- • Inability to administer subcutaneous injections either by self or by caregiver
- • Medical, psychiatric or other conditions that compromise the patient's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study
- • Any significant change in the patient's medical condition after enrollment in Study 307000A which would have lead to his/her exclusion from participation that study
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Kansas City, Missouri, United States
Chicago, Illinois, United States
Winston Salem, North Carolina, United States
San Francisco, California, United States
Chicago, Illinois, United States
Winston Salem, North Carolina, United States
Nashville, Tennessee, United States
Ann Arbor, Michigan, United States
Louisville, Kentucky, United States
Atlanta, Georgia, United States
Los Angeles, California, United States
Durham, North Carolina, United States
Stony Brook, New York, United States
Atlanta, Georgia, United States
Nashville, Tennessee, United States
Kansas City, Missouri, United States
San Francisco, California, United States
Columbus, Mississippi, United States
High Point, North Carolina, United States
Washington, District Of Columbia, United States
Reno, Nevada, United States
Washington, District Of Columbia, United States
Stony Brook, New York, United States
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials